Leukemia Archives | Report Store | Pharma intelligence

Disease Analysis: Acute Myeloid Leukemia (AML)

AML is a type of heterogeneous hematological malignancy that originates from immature white blood cells (blasts) in the bone marrow, which may be derived from either a hematopoietic stem cell or a lineage-specific progenitor cell. “Acute” means that the leukemia may progress rapidly – AML generally spreads quickly to the bloodstream and can then spread to other parts of the body including the lymph nodes, spleen, central nervous system, and testicles.

January 6, 2023

Find out more

Chronic Lymphocytic Leukemia (CLL)

Market Spotlight: Acute Lymphoblastic Leukemia (ALL)

$1,318.00

This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

November 18, 2022

Find out more

Leukemia

Disease Analysis: Acute Myeloid Leukemia (AML)

Chronic Lymphocytic Leukemia (CLL)

Market Spotlight: Acute Lymphoblastic Leukemia (ALL)

Disease Analysis: Chronic Myeloid Leukemia (CML)